Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

摘要: Summary Background Poor treatment results obtained with palliative chemotherapy for advanced gastric cancer indicate the need new effective and well-tolerated regimens Patients methods Forty-three patients locally or metastatic were enrolled in a phase II study to evaluate efficacy safety of combination doxetacel 75 mg/m2 cisplatin given every three weeks Results Thirty-nine evaluable response Four achieved complete twelve partial response, an overall rate 37.2% (16 43 patients; 95% confidence interval (CI) 22 98–53 72) Median time progression was 6 1 months median survival 10 4 Forty-two percent all still alive at one year two years The major toxicity leukopenia which reached grade 3–4 18.6% (n = 8) However, no febrile neutropenia occurred Nonhaematological toxicities usually mild moderate Grade 3 included diarrhea (9% patients), nausea vomiting (7%), alopecia (7%). Severe ototoxicity without peripheral neuropathy developed after completion patients. Conclusions These suggest that docetaxel has is regimen cancer, both regard survival.